313 related articles for article (PubMed ID: 16635784)
21. Novel immunosuppression compounds and experimental therapies for chronic graft-versus-host disease.
Michael M; Shimoni A; Nagler A
Acta Haematol; 2013; 130(1):34-43. PubMed ID: 23392110
[TBL] [Abstract][Full Text] [Related]
22. Design and Patient Characteristics of the Chronic Graft-versus-Host Disease Response Measures Validation Study.
Chronic GVHD Consortium
Biol Blood Marrow Transplant; 2018 Aug; 24(8):1727-1732. PubMed ID: 29476954
[TBL] [Abstract][Full Text] [Related]
23. Meta-analyses and adaptive group sequential designs in the clinical development process.
Jennison C; Turnbull BW
J Biopharm Stat; 2005; 15(4):537-58. PubMed ID: 16022162
[TBL] [Abstract][Full Text] [Related]
24. Understanding graft-versus-host disease. Preliminary findings regarding the effects of exercise in affected patients.
Fiuza-Luces C; Garatachea N; Simpson RJ; Berger NA; RamÃrez M; Lucia A
Exerc Immunol Rev; 2015; 21():80-112. PubMed ID: 25826127
[TBL] [Abstract][Full Text] [Related]
25. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: III. The 2020 Treatment of Chronic GVHD Report.
DeFilipp Z; Couriel DR; Lazaryan A; Bhatt VR; Buxbaum NP; Alousi AM; Olivieri A; Pulanic D; Halter JP; Henderson LA; Zeiser R; Gooley TA; MacDonald KPA; Wolff D; Schultz KR; Paczesny S; Inamoto Y; Cutler CS; Kitko CL; Pidala JA; Lee SJ; Socie G; Sarantopoulos S; Pavletic SZ; Martin PJ; Blazar BR; Greinix HT
Transplant Cell Ther; 2021 Sep; 27(9):729-737. PubMed ID: 34147469
[TBL] [Abstract][Full Text] [Related]
26. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IV. The 2020 Highly morbid forms report.
Wolff D; Radojcic V; Lafyatis R; Cinar R; Rosenstein RK; Cowen EW; Cheng GS; Sheshadri A; Bergeron A; Williams KM; Todd JL; Teshima T; Cuvelier GDE; Holler E; McCurdy SR; Jenq RR; Hanash AM; Jacobsohn D; Santomasso BD; Jain S; Ogawa Y; Steven P; Luo ZK; Dietrich-Ntoukas T; Saban D; Bilic E; Penack O; Griffith LM; Cowden M; Martin PJ; Greinix HT; Sarantopoulos S; Socie G; Blazar BR; Pidala J; Kitko CL; Couriel DR; Cutler C; Schultz KR; Pavletic SZ; Lee SJ; Paczesny S
Transplant Cell Ther; 2021 Oct; 27(10):817-835. PubMed ID: 34217703
[TBL] [Abstract][Full Text] [Related]
27. Chronic graft versus host disease.
Baird K; Pavletic SZ
Curr Opin Hematol; 2006 Nov; 13(6):426-35. PubMed ID: 17053454
[TBL] [Abstract][Full Text] [Related]
28. Rationale and design of the chronic GVHD cohort study: improving outcomes assessment in chronic GVHD.
Chronic GVHD Consortium
Biol Blood Marrow Transplant; 2011 Aug; 17(8):1114-20. PubMed ID: 21664473
[TBL] [Abstract][Full Text] [Related]
29. Adult adherent stromal cells in the management of graft-versus-host disease.
Newell LF; Deans RJ; Maziarz RT
Expert Opin Biol Ther; 2014 Feb; 14(2):231-46. PubMed ID: 24397853
[TBL] [Abstract][Full Text] [Related]
30. Skin response using NIH consensus criteria vs Hopkins scale in a phase II study for steroid-refractory chronic GVHD.
Jacobsohn DA; Rademaker A; Kaup M; Vogelsang GB
Bone Marrow Transplant; 2009 Dec; 44(12):813-9. PubMed ID: 19430498
[TBL] [Abstract][Full Text] [Related]
31. Graft-versus-host disease after marrow transplantation.
Storb R
Prog Clin Biol Res; 1986; 224():139-57. PubMed ID: 3540990
[TBL] [Abstract][Full Text] [Related]
32. Sparing effect by montelukast treatment for chronic graft versus host disease: a pilot study.
Or R; Gesundheit B; Resnick I; Bitan M; Avraham A; Avgil M; Sacks Z; Shapira MY
Transplantation; 2007 Mar; 83(5):577-81. PubMed ID: 17353777
[TBL] [Abstract][Full Text] [Related]
33. ECNP consensus meeting. Bipolar depression. Nice, March 2007.
Goodwin GM; Anderson I; Arango C; Bowden CL; Henry C; Mitchell PB; Nolen WA; Vieta E; Wittchen HU
Eur Neuropsychopharmacol; 2008 Jul; 18(7):535-49. PubMed ID: 18501566
[TBL] [Abstract][Full Text] [Related]
34. Eligibility criteria in randomized phase II and III adjuvant and neoadjuvant breast cancer trials: not a significant barrier to enrollment.
Filion M; Forget G; Brochu O; Provencher L; Desbiens C; Doyle C; Poirier B; DuRocher M; Camden S; Lemieux J
Clin Trials; 2012 Oct; 9(5):652-9. PubMed ID: 23060323
[TBL] [Abstract][Full Text] [Related]
35. Biostatistical methods for demonstrating efficacy in the regulatory setting. An epistemological approach to adaptive designs.
Koch A
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2005 May; 48(5):572-9. PubMed ID: 15887068
[TBL] [Abstract][Full Text] [Related]
36. Daclizumab for children with corticosteroid refractory graft-versus-host disease.
Teachey DT; Bickert B; Bunin N
Bone Marrow Transplant; 2006 Jan; 37(1):95-9. PubMed ID: 16247417
[TBL] [Abstract][Full Text] [Related]
37. Rationale and design of the enoximone clinical trials program.
Lowes BD; Shakar SF; Metra M; Feldman AM; Eichhorn E; Freytag JW; Gerber MJ; Liard JF; Hartman C; Gorczynski R; Evans G; Linseman JV; Stewart J; Robertson AD; Roecker EB; Demets DL; Bristow MR
J Card Fail; 2005 Dec; 11(9):659-69. PubMed ID: 16360960
[TBL] [Abstract][Full Text] [Related]
38. Pharmacologic prophylaxis of acute graft-versus-host disease after allogeneic marrow transplantation.
Schwinghammer TL; Bloom EJ
Clin Pharm; 1993 Oct; 12(10):736-61. PubMed ID: 8258255
[TBL] [Abstract][Full Text] [Related]
39. Treatment of acute graft-versus-host disease with methylprednisolone and cyclosporine with or without an anti-interleukin-2 receptor monoclonal antibody. A multicenter phase III study.
Cahn JY; Bordigoni P; Tiberghien P; Milpied N; Brion A; Widjenes J; Lioure B; Michel G; Burdach S; Kolb HJ
Transplantation; 1995 Nov; 60(9):939-42. PubMed ID: 7491697
[TBL] [Abstract][Full Text] [Related]
40. Ancillary and supportive care in chronic graft-versus-host disease.
Couriel DR
Best Pract Res Clin Haematol; 2008 Jun; 21(2):291-307. PubMed ID: 18503994
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
